mb-102
Cell therapyexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02772276)
Timeline
Indications
Studied for
- Acute Kidney Injury · Phase 2
- Crohn Disease · Early Phase 1
- Diabetic Retinopathy · Early Phase 1
- Kidney Diseases · Phase 3
- Macular Degeneration · Early Phase 1
- Plasmacytoma · Phase 1/Phase 2
- Renal Insufficiency · Phase 3
- Renal Insufficiency, Chronic · Phase 3
- Retinal Diseases · Early Phase 1
- Retinal Vein Occlusion · Early Phase 1
Mechanism of action
- Interleukin-3 receptor subunit alphaImmunity, passive
IL3RA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mb-102
- mb-102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05777174 | Phase 3 | Mar 20, 2023 | MediBeacon |
| NCT05425719 | Phase 3 | Jun 14, 2022 | MediBeacon |
| NCT04109482 | Phase 1/Phase 2 (Phase 2) | Oct 16, 2019 | City of Hope National Medical Center, Fortress Biotech |
| NCT03962998 | Early Phase 1 (Phase 1) | Aug 31, 2019 | MediBeacon |
| NCT04008121 | Early Phase 1 (Phase 1) | Jul 31, 2019 | MediBeacon |
| NCT02772276 | Phase 2 | Jul 1, 2016 | MediBeacon |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MediBeacon | For profit | 5 | 5 | 3 | 2016 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Fortress Biotech | For profit | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1